## **Learning Objectives**

By the end of this lecture, you should be able to:

1. Describe the **structure and function** of the **Naâº/Kâº ATPase (sodium pump)**.
    
2. Explain how the pump **maintains ionic gradients** across membranes.
    
3. Discuss the **clinical significance** of cardiac glycosides (e.g., **digoxin**) and **potassium levels**.
    
4. Compare **primary vs secondary active transport** with examples.
    
5. Explain **Naâº-dependent CaÂ²âº transport** and **transepithelial glucose transport**.
    

---

## **1. The Problem: Maintaining Ionic Steady State**

Cells must maintain:

- High **[Kâº] inside** (â‰ˆ 140 mM)
    
- Low **[Naâº] inside** (â‰ˆ 10 mM)
    
- High **[Naâº] outside** (â‰ˆ 140 mM)
    
- Low **[Kâº] outside** (â‰ˆ 5 mM)
    

ğŸ‘‰ **Diffusion** alone would equalise these concentrations, so active mechanisms are required to maintain them.

**Solution:** The **sodium pump (Naâº/Kâº ATPase)** continually **expels Naâº** and **imports Kâº**, maintaining this imbalance.

---

## **2. The Sodium Pump â€“ Overview**

- An **integral membrane protein** that **uses ATP** to pump ions **against their gradients**.
    
- **3 Naâº out / 2 Kâº in per ATP** hydrolysed.
    
- Found in almost all cell membranes.
    

**Functions:**

- Maintains **electrochemical gradients** for Naâº and Kâº.
    
- Generates **resting membrane potential** (net + charge lost â†’ inside negative).
    
- Regulates **cell volume** (prevents osmotic swelling).
    
- Drives **secondary active transport** (e.g., glucose and calcium exchange).
    

---

## **3. Sodium Pump Structure**

|Subunit|Function|MW|
|---|---|---|
|**Î±-subunit**|Catalytic: binds **ATP**, **3 Naâº (internal)**, **2 Kâº (external)**|~100 kDa|
|**Î²-subunit**|Stabilises the Î±-subunit; assists in membrane insertion|~40 kDa|

- Functional form = **Î±â‚‚Î²â‚‚ tetramer** (MW â‰ˆ 280 kDa).
    
- **ATP binding site** and **Naâº/Kâº binding sites** are on Î±-subunit.
    
- **Cardiac glycosides (digoxin, ouabain)** bind to **extracellular Kâº site** on Î±-subunit.
    

**Exam Focus:**  
Be able to label Î±/Î² subunits, binding sites, and explain 3 Naâº out : 2 Kâº in stoichiometry.

---

## **4. Sodium Pump Reaction Equation**

[3Na+]iâ€‹+[2K+]oâ€‹+ATP  ----(Na++K+)ATPase---->â€‹[3Na+]oâ€‹+[2K+]iâ€‹+ADP+Pi+energy

- Each cycle hydrolyses **1 ATP** to **ADP + Pi**.
    
- **Km (Michaelis constant):**
    
    - **Naâº Km = 20 mM**
        
    - **Kâº Km = 1 mM**
        
- Intracellular Naâº (~10 mM) = **rate-limiting** under normal conditions.
    

**Enzyme kinetics insight:**  
Higher Km = lower affinity â†’ pump rate depends more on [Naâº]áµ¢ changes.

---

## **5. Pump Kinetics & Regulation**

- Each pump cycle â‰ˆ **100 cycles per second**.
    
- **Inhibited** by â†“ [Kâº]â‚’ or cardiac glycosides (digoxin).
    
- **Stimulated** by â†‘ [Naâº]áµ¢.
    
- Most cells have **~1 million Naâº/Kâº pump sites**.
    

---

## **6. Mechanism of Naâº/Kâº ATPase (Cycle)**

1. **3 Naâº bind** to the **intracellular Î±-subunit**.
    
2. **ATP binds**, hydrolysed â†’ **phosphorylation** of the pump.
    
3. Conformational change â†’ **3 Naâº released** outside.
    
4. **2 Kâº bind externally**, causing **dephosphorylation**.
    
5. Pump returns to resting conformation â†’ **2 Kâº enter** cytoplasm.
    

**Net effect:** 1 positive charge **lost** â†’ contributes to **negative resting potential**.

---

## **7. Role in Maintaining Cell Volume**

- Small leak of Naâº into cell â†’ water follows osmotically.
    
- Pump continuously **expels Naâº**, preventing **swelling & lysis**.
    
- Without Naâº/Kâº ATPase, intracellular Naâº â†‘ â†’ osmotic water influx â†’ **cell bursts**.
    

**Clinical Focus:**

- Naâº/Kâº pump essential for **neural excitability**, **osmotic stability**, and **secondary active transport** (e.g., glucose uptake).
    

---

## **8. Cardiac Glycosides (e.g., Digoxin)**

- **Inhibit Naâº/Kâº ATPase** by binding to **extracellular Kâº site** on Î±-subunit.
    
- Leads to **â†‘ intracellular Naâº**, which reduces activity of **Naâº/CaÂ²âº exchanger**.  
    â†’ Result: **â†‘ intracellular CaÂ²âº** â†’ **stronger cardiac contraction** (positive inotropy).
    

**Clinical Application:**

- Used in **heart failure** and **atrial fibrillation** to improve contractility and control rate.
    

---

## **9. Effect of Potassium on Digoxin**

- **[Kâº]â‚’ competes with digoxin** for binding sites.
    
- â†“ [Kâº]â‚’ (**hypokalaemia**) â†’ **increased digoxin binding** â†’ toxicity.
    
- â†‘ [Kâº]â‚’ (**hyperkalaemia**) â†’ **reduced digoxin effect**.
    

ğŸ©º **Clinical Focus:**  
Always monitor **serum Kâº** in patients on **digoxin**, especially if on **diuretics** (which cause Kâº loss).

**Summary:**

|Condition|Effect on Digoxin|Outcome|
|---|---|---|
|Hypokalaemia|â†‘ binding|â†‘ toxicity risk|
|Hyperkalaemia|â†“ binding|â†“ efficacy|

---

## **10. Therapeutic Index (TI)**

\text{TI} = \frac{\text{Toxic dose for 50% (TDâ‚…â‚€)}}{\text{Effective dose for 50% (EDâ‚…â‚€)}}

- **Digoxin TI â‰ˆ 2:1 â†’ very narrow safety margin.**
    
    - Compare:
        
        - Remifentanil â€“ 33,000:1
            
        - Diazepam â€“ 100:1
            
        - Ethanol â€“ 10:1
            

**Clinical Relevance:**  
Small changes in plasma [Kâº] or digoxin dose â†’ **toxic arrhythmias**.

---

## **11. Blood Potassium Levels**

|Range (mEq/L)|Classification|Clinical Features|
|---|---|---|
|< 3.5|**Hypokalaemia**|Arrhythmias, muscle weakness, paralysis|
|3.6â€“5.2|**Normal (normokalaemia)**|Normal muscle/heart function|
|> 5.5|**Hyperkalaemia**|Muscle weakness, nausea, cardiac arrest (>7.0 mEq/L)|

ğŸ§  **Exam Focus:**  
Know how [Kâº]â‚’ affects cardiac excitability and **digoxin binding**.

---

## **12. Primary vs Secondary Active Transport**

|Type|Energy Source|Example|Notes|
|---|---|---|---|
|**Primary**|Direct ATP hydrolysis|Naâº/Kâº ATPase|Moves ions directly using ATP|
|**Secondary**|Uses Naâº gradient (from Naâº/Kâº pump)|Naâº/glucose cotransport|Couples ion movement with solute transport|

---

## **13. Sodiumâ€“Calcium Exchanger (Antiport)**

- **Secondary active counter-transport.**
    
- 3 Naâº in : 1 CaÂ²âº out.
    
- Driven by Naâº electrochemical gradient (created by Naâº/Kâº ATPase).
    
- Keeps **intracellular CaÂ²âº low**, vital for **muscle relaxation**.
    

**Clinical Relevance:**

- In cardiac muscle, digoxin **reduces Naâº/CaÂ²âº exchange** â†’ **â†‘ intracellular CaÂ²âº** â†’ **enhanced contraction**.
    

---

## **14. Sodium-Dependent Glucose Transport (Co-transport)**

- **Secondary active co-transport** (symport).
    
- Uses **Naâº gradient** to move glucose **into cells** (e.g., intestinal & renal epithelia).
    

|Transporter|Location|Naâº:Glucose Ratio|Function|
|---|---|---|---|
|**SGLT1**|Small intestine|2:1|High affinity (Km 0.8 mM)|
|**SGLT2**|Kidney proximal tubule|1:1|Low affinity (Km 1.6 mM)|

**Steps:**

1. **Apical membrane:** Naâº and glucose enter via **SGLT1** (secondary active).
    
2. **Basolateral membrane:** Glucose exits via **GLUT2** (facilitated diffusion).
    
3. Naâº gradient maintained by **Naâº/Kâº ATPase**.
    

**Clinical Focus:**

- **SGLT2 inhibitors** (e.g., _dapagliflozin_) reduce glucose reabsorption in diabetes.
    

---

## **15. Case Study â€“ â€œEthelâ€**

**Background:**  
Elderly patient on **digoxin** for atrial fibrillation â†’ presents with **pulmonary oedema** and **hypokalaemia** after receiving **furosemide** (loop diuretic).

### Mechanism:

- **Furosemide** â†‘ urinary Kâº loss â†’ **hypokalaemia**.
    
- â†“ Kâº â†’ â†‘ digoxin binding â†’ **digoxin toxicity**.
    
- Toxicity â†’ excessive Naâº pump inhibition â†’ **â†‘ intracellular Naâº** â†’ **CaÂ²âº overload** â†’ arrhythmia.
    

### Management:

- Administer **Digibind** (digoxin-binding antibody) â†’ neutralises digoxin â†’ reverses toxicity.
    

ğŸ©º **Clinical Takeaway:**  
Patients on **digoxin + diuretics** require **close Kâº monitoring** to prevent **fatal arrhythmias**.

---

## âœ… **Exam Focus Summary**

|Concept|Key Points|
|---|---|
|**Naâº/Kâº pump**|3 Naâº out : 2 Kâº in, ATP hydrolysis, maintains gradients|
|**Pump structure**|Î± (ATPase, Naâº/Kâº binding) + Î² (stabiliser) subunits|
|**Digoxin mechanism**|Inhibits pump â†’ â†‘ Naâº â†’ â†“ Naâº/CaÂ²âº exchange â†’ â†‘ CaÂ²âº|
|**Kâº & digoxin**|Hypokalaemia â†‘ toxicity, hyperkalaemia â†“ effect|
|**Therapeutic index**|Digoxin = narrow (2:1) â†’ high toxicity risk|
|**Primary vs secondary transport**|ATP use vs Naâº gradient use|
|**Sodiumâ€“calcium exchanger**|3 Naâº in : 1 CaÂ²âº out (antiport)|
|**SGLT1/2**|Naâº-dependent glucose co-transporters|
|**Case study**|Loop diuretic + digoxin â†’ hypokalaemia â†’ digoxin toxicity|